Neuraminidase inhibitors for the treatment and prevention of influenza

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 2, 2002, Pages 103-112

  McKimm Breschkin, Jennifer L ^a  

^a CSIRO   (Australia)

Author keywords

BCX 1812; Influenza; Neuraminidase inhibitors; Oseltamivir; RWJ 270201; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BRONCHODILATING AGENT; INFLUENZA VACCINE; N ACETYL 2,3 DIDEHYDRO 2 DEOXYNEURAMINIC ACID; NEW DRUG; OSELTAMIVIR; PERAMIVIR; PLACEBO; PRODRUG; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; CHILD; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DESIGN; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TISSUE LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; METERED DOSE INHALER; MOUSE; NONHUMAN; REVIEW; SYMPTOM; VIRUS INHIBITION; VIRUS MUTATION;

ACETAMIDES; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; PYRANS; RANDOMIZED CONTROLLED TRIALS; SIALIC ACIDS; TREATMENT OUTCOME; ZANAMIVIR;

EID: 0036166775     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.2.103     Document Type: Review

References (86)

1. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults
2. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses
3. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use
4. Low incidence of rimantadine resistance in field isolates of influenza A viruses
5. Nasal cytokine and chemokine responses in experimental influenza A virus infection: Results of a placebo-controlled trial of iv. zanamivir treatment
6. Rational design of potent sialidase-based inhibitors of influenza virus replication
7. Influenza virus neuraminidase: Structure, antibodies and inhibitors
8. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob
9. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity
10. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally-active and selective influenza neuraminidase inhibitor through structure-based drug design
11. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir
12. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201
13. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities
14. Influence of virus strain, challenge dose and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201
15. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A in health adult volunteers
16. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing
17. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
18. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomised, double-blind, placebo-controlled European study
19. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally-occurring influenza in otherwise healthy adults
20. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: Results from Japan
21. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
22. Zanamivir for the treatment of influenza A and B infection in high-risk patients: A pooled analysis of randomised controlled trials
23. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults
24. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
25. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: Randomised controlled trial
26. Bronchospasm with zanamivir
27. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir
28. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease
29. NICE issues guidance on zanamamivir (Relenza) for influenza
30. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group
31. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomised controlled trial
32. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomised controlled trials for prevention and treatment
33. Oral oseltamivir in human experimental influenza B infection
34. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802
35. Oral oseltamivir treatment of influenza in children
36. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob
37. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses
38. Characterization of the 1918 'Spanish' influenza virus neuraminidase gene
39. Zanamivir in the prevention of influenza among healthy adults: A randomised controlled trial
40. Short-term treatment with zanamivir to prevent influenza: Results of a placebo-controlled study
41. Inhaled zanamivir for the prevention of influenza in families
42. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home
43. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
44. Effectiveness of oseltamivir in preventing influenza in household contacts: A randomised controlled trial
45. Experience with oseltamivir in the control of a nursing home influenza B outbreak
46. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population
47. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice
48. Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice
49. The effect of zanamivir treatment on the early immune response to influenza vaccination
50. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers
51. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice
52. Zanamivir, a new targeted therapy in the treatment of influenza. A patient perspective assessed by questionnaire
53. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: Randomised controlled trial
54. Elderly people's technique in using dry powder inhalers. Zanamivir and unreason seem to go together
55. Resistance of influenza viruses to neuraminidase inhibitors - A review
56. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en
57. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors
58. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en
59. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
60. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors
61. Inhibition of influenza virus haemagglutinin-mediated membrane fusion by a compound related to podocarpic acid
62. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase
63. Molecular basis for the resistance of influenza viruses to 4-guanidino- Neu5Ac2en
64. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir
65. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
66. Virological assessment in vitro and in vivo of an influenza H1N1 virus with a H274Y mutation in the neuraminidase gene
67. Characterization of an influenza A virus variant selected in vitro in the presence of the neuraminidase inhibitor, GS4071
68. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
69. Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase
70. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular and sialidase from influenza virus types A and B
71. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme
72. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during Phase II clinical efficacy studies
73. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
74. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid
75. An oseltamivir treatment-selected influenza A:N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo
76. Oseltamivir treatment of experimental influenza A/Texas/36/91 (H1N1) virus infection in humans: Selection of a novel neuraminidase variant
77. Management of influenza. Use of new antivirals and resistance in perspective
78. Generation and characterization of a mutant of influenza A virus selected with neuraminidase inhibitor RWJ-270201
79. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201
80. Position statement: Global neuraminidase inhibitor susceptibility network
81. Economic burden of influenza-like illness in long-term-care facilities
82. The socio-economic burden of influenza
83. Influenza. The role of burden-of-illness research
84. The economic impact of pandemic influenza in the United States: Priorities for intervention
85. Clinical signs and symptoms predicting influenza infection